Cargando…
NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance
In a phase IV trial, eighty-four patients (age 18–79) with acute myeloid leukemia (AML) in first complete remission (CR) received cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose human recombinant interleukin-2 (IL-2) to prevent relapse in the post-consolidation phase. Aspec...
Autores principales: | Martner, Anna, Rydström, Anna, Riise, Rebecca E., Aurelius, Johan, Brune, Mats, Foà, Robin, Hellstrand, Kristoffer, Thorén, Fredrik B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767453/ https://www.ncbi.nlm.nih.gov/pubmed/26544512 |
Ejemplares similares
-
Role of natural killer cell subsets and natural cytotoxicity receptors for
the outcome of immunotherapy in acute myeloid leukemia
por: Martner, Anna, et al.
Publicado: (2015) -
Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia
por: Sander, Frida Ewald, et al.
Publicado: (2016) -
Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy
por: Sander, Frida Ewald, et al.
Publicado: (2017) -
Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance
por: Grauers Wiktorin, Hanna, et al.
Publicado: (2021) -
Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse‐preventive immunotherapy in acute myeloid leukaemia
por: Nilsson, Malin S., et al.
Publicado: (2019)